Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in active primary Sjogren's syndrome
2020-003298-22Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing GLPG3970 with Placebo (2 arms). Primary endpoint: Change from baseline in EULAR Sjogren's Syndrome Disease Activity Index. Started Nov 2020; status: terminated.
02
Drugs
GLPG3970
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2020-003298-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003298-22.